Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Filgrastim 9Cytarabine 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 6Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cladribine 5Mitoxantrone 4Methotrexate 4Cyclophosphamide 4Melphalan 3Injections 3Cyclosporine 3Biopsy 3venetoclax 2revumenib 2pegylated granulocyte colony-stimulating factor 2X-Rays 2Trimethoprim, Sulfamethoxazole Drug Combination 2Tacrolimus 2Specimen Handling 2Idarubicin 2Decitabine 2Daunorubicin 2Clofarabine 2Busulfan 2Bone Marrow Transplantation 2quizartinib 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Biphenotypic, Acute × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡